Back to Browse Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

Intravenous magnetic nanoparticle cancer hyperthermia

Authors Huang HS, Hainfeld JF

Published Date July 2013 Volume 2013:8(1) Pages 2521—2532

DOI http://dx.doi.org/10.2147/IJN.S43770

Received 7 February 2013, Accepted 22 March 2013, Published 17 July 2013

Video abstract presented by HS Huang and JF Hainfeld.

Views: 728

Hui S Huang, James F Hainfeld

Nanoprobes, Yaphank, NY, USA

Abstract: Magnetic nanoparticles heated by an alternating magnetic field could be used to treat cancers, either alone or in combination with radiotherapy or chemotherapy. However, direct intratumoral injections suffer from tumor incongruence and invasiveness, typically leaving undertreated regions, which lead to cancer regrowth. Intravenous injection more faithfully loads tumors, but, so far, it has been difficult achieving the necessary concentration in tumors before systemic toxicity occurs. Here, we describe use of a magnetic nanoparticle that, with a well-tolerated intravenous dose, achieved a tumor concentration of 1.9 mg Fe/g tumor in a subcutaneous squamous cell carcinoma mouse model, with a tumor to non-tumor ratio > 16. With an applied field of 38 kA/m at 980 kHz, tumors could be heated to 60°C in 2 minutes, durably ablating them with millimeter (mm) precision, leaving surrounding tissue intact.

Keywords: magnetic nanoparticles, hyperthermia, cancer, alternating magnetic field, intravenous delivery

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Barium titanate core – gold shell nanoparticles for hyperthermia treatments

FarrokhTakin E, Ciofani G, Puleo GL, de Vito G, Filippeschi C, Mazzolai B, Piazza V, Mattoli V

International Journal of Nanomedicine 2013, 8:2319-2331

Published Date: 28 June 2013

Novel thermosensitive hydrogel for preventing formation of abdominal adhesions

Gao X, Deng XH, Wei XW, Shi HS, Wang FT, Ye TH, Shao B, Nie W,Li YL, Luo M, Gong CY, Huang N

International Journal of Nanomedicine 2013, 8:2453-2463

Published Date: 11 July 2013

Cytotoxicity of nickel zinc ferrite nanoparticles on cancer cells of epithelial origin

Al-Qubaisi MS, Rasedee A, Flaifel MH, Ahmad SHJ, Hussein-Al-Ali S, Hussein MZ, Eid EEM, Zainal Z, Saeed M, Ilowefah M, Fakurazi S, Mohd Isa N, El Zowalaty ME

International Journal of Nanomedicine 2013, 8:2497-2508

Published Date: 15 July 2013

The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation

Yu KF, Zhang WQ, Luo LM, Song P, Li D, Du R, Ren W, Huang D, Lu WL, Zhang X, Zhang Q

International Journal of Nanomedicine 2013, 8:2473-2485

Published Date: 15 July 2013

Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma

Gong DJ, Zhang JM, Yu M, Zhuang B, Guo QQ

Clinical Interventions in Aging 2013, 8:889-897

Published Date: 16 July 2013

Progress toward therapeutic potential for AFQ056 in Fragile X syndrome

Sourial M, Cheng C, Doering LC

Journal of Experimental Pharmacology 2013, 5:45-54

Published Date: 17 July 2013

A case of Alagille syndrome complicated by intraocular lens subluxation and rhegmatogenous retinal detachment

Fukumoto M, Ikeda T, Sugiyama T, Ueki M, Sato T, Ishizaki E

Clinical Ophthalmology 2013, 7:1463-1465

Published Date: 17 July 2013

Organelle targeting: third level of drug targeting

Sakhrani NM, Padh H

Drug Design, Development and Therapy 2013, 7:585-599

Published Date: 17 July 2013

Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γH2AX

Takatori E, Shoji T, Sawai T, Kurose A, Sugiyama T

OncoTargets and Therapy 2013, 6:901-907

Published Date: 17 July 2013